Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
McKesson
US Department of Justice
Julphar
Medtronic
UBS
Federal Trade Commission
Cantor Fitzgerald
Daiichi Sankyo

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,888,364

« Back to Dashboard

Which drugs does patent 7,888,364 protect, and when does it expire?

Patent 7,888,364 protects ERIVEDGE and is included in one NDA.

This patent has forty patent family members in twenty-two countries.
Summary for Patent: 7,888,364
Title:Pyridyl inhibitors of hedgehog signalling
Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: ##STR00001## wherein A, X, Y R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n are as described herein.
Inventor(s): Gunzner; Janet L. (Berkeley, CA), Sutherlin; Daniel (South San Francisco, CA), Stanley; Mark S. (Pacifica, CA), Bao; Liang (San Mateo, CA), Castanedo; Georgette M. (Redwood City, CA), Lalonde; Rebecca L. (Berkeley, CA), Wang; Shumei (Foster City, CA), Reynolds; Mark E. (Millbrae, CA), Savage; Scott J. (Burlingame, CA), Malesky; Kimberly (San Francisco, CA), Dina; Michael S. (Daly City, CA)
Assignee: Curis, Inc. (Cambridge, MA)
Application Number:11/217,663
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,888,364

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,888,364

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,278,961 Pyridyl inhibitors of hedgehog signalling ➤ Sign Up
9,790,183 Pyridyl inhibitors of hedgehog signalling ➤ Sign Up
9,321,761 Pyridyl inhibitors of hedgehog signalling ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fuji
Cerilliant
Cantor Fitzgerald
QuintilesIMS
Mallinckrodt
Teva
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.